| Oneirogen | |
|---|---|
| Drug class | |
Chemical structure of ibogaine, the main active constituent of Tabernanthe iboga and among the most well-known oneirogens. | |
| Class identifiers | |
| Synonyms | Oneirophrenic; Oneiric; Ibogaine-type hallucinogen; Harmaline-type hallucinogen |
| Use | Recreational, spiritual, medical |
| Mechanism of action | Unknown |
| Biological target | Unknown |
| Chemical class | Azepinoindoles (e.g., ibogaine), β-carbolines (e.g., harmaline) |
| Legal status | |
| Legal status | |
| In Wikidata | |
An oneirogen (from the Greek ὄνειρος óneiros meaning "dream" and gen "to create") is a drug that induces a dream-like state of consciousness, also known as oneirophrenia.
The term oneirogen, oneirophrenic, or oneiric, was introduced to refer specifically to ibogaine- and harmaline-type hallucinogens by William Turner and Claudio Naranjo in the 1960s and 1970s. Subsequently, the term has also sometimes been used to refer to non-hallucinogenic drugs that facilitate dreaming.
Hallucinogenic oneirogens include the following:
These compounds are notable in being structurally similar cyclized tryptamines and in being structurally related to psychedelic tryptamines. For example, ibogaine is a cyclized derivative of 5-MeO-DMT, while harmaline is a cyclized derivative of 6-MeO-DMT.
The hallucinogenic effects of these drugs are qualitatively unique and have been described as a "dream-like" altered state of consciousness. Iboga alkaloids and β-carbolines or harmala alkaloids have similar qualitative effects, but despite their structural relation to tryptamine psychedelics, show distinct and dissimilar subjective effects from those of serotonergic psychedelics like LSD, psilocybin, and mescaline.
Ibogaine and noribogaine are so-called "dirty drugs" that are known to interact with numerous targets. However, the precise mechanism of action of oneirogens like ibogaine, or whether their hallucinogenic effects are due to multiple concomitant activities, are unknown. While they can bind to the serotonin 5-HT2A receptor similarly to serotonergic psychedelics, neither iboga alkaloids nor β-carbolines actually activate the receptor, unlike psychedelics. In addition, ibogaine does not produce the head-twitch response, a behavioral proxy of serotonergic psychedelic effects, in rodents. Noribogaine, the major active metabolite and form of ibogaine, is known to be a potent atypical κ-opioid receptor agonist. However, harmala alkaloids like harmaline do not interact with the κ-opioid receptor. Similarly, the NMDA receptor and the sigma σ1 receptor do not appear to be involved in the subjective effects of ibogaine based on animal studies.
| Compound | Chemical name | Dose (hallucinogen) | Potency | Dose (MAOI) | Duration |
|---|---|---|---|---|---|
| Harman | 1-Methyl-β-carboline | >250 mg | Unknown | >250 mg | Unknown |
| Harmine | 7-Methoxyharman | >300 mg | ≤50% | 140–250 mg | 6–8 hours |
| Harmaline | 7-Methoxy-3,4-dihydroharman | 150–400 mg | 100% | 70–150 mg | 5–8 hours |
| Tetrahydroharmine | 7-Methoxy-1,2,3,4-tetrahydroharman | ≥300 mg | ~33% | Unknown | Unknown |
| 6-Methoxyharmalan | 6-Methoxy-3,4-dihydroharman | ~100 mg | ~150% | Unknown | Unknown |
| 6-MeO-THH | 6-Methoxy-1,2,3,4-tetrahydroharman | ≥100 mg | ~50% | Unknown | Unknown |
| P. harmala seeds | – | ≥5–28 ga | – | 3–5 ga | Unknown |
| Footnotes: a = P. harmala seeds in ground form. They contain 2–7% harmala alkaloids, with 1 teaspoon ≈ 3 g ≈ 60–180 mg alkaloids; 1 tablespoon ≈ 9 g ≈ 200–600 mg alkaloids; and 1 large (OO) gelatin capsule ≈ 0.7 g ≈ 15–45 mg alkaloids. For comparison, B. caapi contains 0.05–1.95% (average 0.45%) harmala alkaloids. Note: Harmine and other β-carbolines have also been tested by non-oral routes such as sublingual, subcutaneous injection, intramuscular injection, and intravenous injection. Refs: See template page. | |||||